MA40662B1 - Anticorps contre tigit - Google Patents
Anticorps contre tigitInfo
- Publication number
- MA40662B1 MA40662B1 MA40662A MA40662A MA40662B1 MA 40662 B1 MA40662 B1 MA 40662B1 MA 40662 A MA40662 A MA 40662A MA 40662 A MA40662 A MA 40662A MA 40662 B1 MA40662 B1 MA 40662B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- antibodies against
- treatment
- against tigit
- fragments
- Prior art date
Links
- 101100369641 Mus musculus Tigit gene Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des anticorps, ou des fragments liant l'antigène de ceux-ci, qui se lient à un tigit (immunorécepteur de cellule t avec des domaines d'ig et d'itim) humain, ainsi que des utilisations de ces anticorps ou fragments dans des applications thérapeutiques, par exemple dans le traitement du cancer ou d'une infection virale chronique. Ce procédé de traitement comprend un traitement combiné avec des inhibiteurs d'autres interactions avec des récepteurs immunomodulateurs, comme une i
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096267P | 2014-12-23 | 2014-12-23 | |
PCT/US2015/067332 WO2016106302A1 (fr) | 2014-12-23 | 2015-12-22 | Anticorps contre tigit |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40662A1 MA40662A1 (fr) | 2020-06-30 |
MA40662B1 true MA40662B1 (fr) | 2020-12-31 |
Family
ID=55168435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40662A MA40662B1 (fr) | 2014-12-23 | 2015-12-22 | Anticorps contre tigit |
Country Status (24)
Country | Link |
---|---|
US (3) | US10189902B2 (fr) |
EP (2) | EP4249066A3 (fr) |
JP (5) | JP6180663B2 (fr) |
KR (1) | KR102644115B1 (fr) |
CN (3) | CN107207594B (fr) |
AR (1) | AR103268A1 (fr) |
AU (2) | AU2015369683C1 (fr) |
BR (1) | BR112017013385A2 (fr) |
CA (1) | CA2971732A1 (fr) |
CL (1) | CL2017001660A1 (fr) |
CO (1) | CO2017006989A2 (fr) |
EA (1) | EA039219B1 (fr) |
IL (2) | IL253013B (fr) |
MA (1) | MA40662B1 (fr) |
MX (2) | MX2017007744A (fr) |
MY (1) | MY187045A (fr) |
PE (1) | PE20171244A1 (fr) |
PH (1) | PH12017501166A1 (fr) |
SG (2) | SG11201705063VA (fr) |
TN (1) | TN2017000267A1 (fr) |
TW (1) | TWI708786B (fr) |
UY (1) | UY36471A (fr) |
WO (1) | WO2016106302A1 (fr) |
ZA (2) | ZA201704981B (fr) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2279412B1 (fr) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire |
US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
HRP20230078T1 (hr) | 2011-09-23 | 2023-05-12 | Mereo Biopharma 5, Inc. | Sredstva za vezivanje vegf/dll4 i njihova uporaba |
KR102256152B1 (ko) | 2013-12-12 | 2021-05-27 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Pd-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102050082B1 (ko) | 2014-08-19 | 2019-11-29 | 머크 샤프 앤드 돔 코포레이션 | 항-tigit 항체 |
WO2016134335A2 (fr) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Polypeptides pvrig et méthodes de traitement |
ES2786651T3 (es) | 2015-02-19 | 2020-10-13 | Compugen Ltd | Anticuerpos anti-PVRIG y métodos de uso |
TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
US10766957B2 (en) | 2015-08-14 | 2020-09-08 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
BR112018067458A2 (pt) | 2016-03-04 | 2019-01-02 | Abmuno Therapeutics Llc | anticorpos para tigit |
CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
MX2018016364A (es) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anticuerpos anti-pd-l1. |
CN107698684B (zh) * | 2016-08-03 | 2021-09-28 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白 |
CN109689688B (zh) | 2016-08-09 | 2023-06-13 | 科马布有限公司 | 抗icos抗体 |
KR102450208B1 (ko) * | 2016-08-17 | 2022-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
WO2018041120A1 (fr) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Animal non humain génétiquement modifié avec un tigit humain ou chimérique |
CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CA3037380A1 (fr) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anticorps anti-lag-3 et leurs procedes d'utilisation |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
EP3548071A4 (fr) * | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | Méthodes de traitement du cancer comprenant des agents de liaison à tigit |
US10759855B2 (en) * | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
WO2018128939A1 (fr) * | 2017-01-05 | 2018-07-12 | Gensun Biopharma Inc. | Antagonistes de régulateur de point de contrôle |
MX2019010206A (es) * | 2017-02-28 | 2019-12-11 | Seattle Genetics Inc | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). |
JOP20190203A1 (ar) * | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
KR20190137911A (ko) | 2017-04-21 | 2019-12-11 | 신라젠(주) | 항암 백시니아 바이러스와 관문 저해제 병용 요법 |
JP2020517699A (ja) * | 2017-04-26 | 2020-06-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ジスルフィド結合の還元を最小限にする抗体製造法 |
DK3618863T3 (da) | 2017-05-01 | 2023-08-21 | Agenus Inc | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618871A4 (fr) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 |
KR20190142394A (ko) * | 2017-05-02 | 2019-12-26 | 머크 샤프 앤드 돔 코포레이션 | 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법 |
CN116333129A (zh) * | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
SG10202111336RA (en) | 2017-06-01 | 2021-11-29 | Compugen Ltd | Triple combination antibody therapies |
WO2018229163A1 (fr) | 2017-06-14 | 2018-12-20 | King's College London | Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
WO2019023504A1 (fr) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | Anticorps anti-tigit |
BE1025333B1 (fr) * | 2017-07-27 | 2019-01-23 | Iteos Therapeutics S.A. | Anticorps anti-tigit |
EP3719040A1 (fr) * | 2017-07-27 | 2020-10-07 | iTeos Therapeutics SA | Anticorps anti-tigit |
CN109425736B (zh) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | 一种检测pd-1抗体血药浓度的方法及试剂盒 |
US11698358B2 (en) | 2017-09-07 | 2023-07-11 | Bristol-Myers Squibb Company | Method of purity determination by capillary electrophoresis |
JP2020533362A (ja) * | 2017-09-13 | 2020-11-19 | テネオバイオ, インコーポレイテッド | エクト酵素に結合する重鎖抗体 |
CN111051347B (zh) * | 2017-09-29 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
US20190099506A1 (en) * | 2017-10-02 | 2019-04-04 | Bristol-Myers Squibb Company | Methods and compositions for deuterated biologics |
KR20200100113A (ko) * | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
WO2019122882A1 (fr) | 2017-12-19 | 2019-06-27 | Kymab Limited | Anticorps bispécifique pour icos et pd-l1 |
AU2018396970A1 (en) | 2017-12-28 | 2020-08-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
TW202400654A (zh) * | 2017-12-30 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
JP7316284B2 (ja) | 2018-01-15 | 2023-07-27 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Tigitに対する抗体及びその多様体 |
KR102224556B1 (ko) | 2018-02-06 | 2021-03-09 | 아이-맵 바이오파마 유에스 리미티드 | Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용 |
MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
SG11202008767XA (en) * | 2018-03-23 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against mica and/or micb and uses thereof |
AU2019241978A1 (en) * | 2018-03-26 | 2020-11-05 | Regeneron Pharmaceuticals, Inc. | Anti-PfRH5 antibodies and antigen-binding fragments thereof |
CR20200450A (es) | 2018-04-02 | 2021-02-11 | Bristol Myers Squibb Co | Anticuerpos anti-trem-l y usos de los mismos |
EP3781599A1 (fr) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées |
US20190365861A1 (en) | 2018-04-18 | 2019-12-05 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
EP3802605A1 (fr) | 2018-06-01 | 2021-04-14 | Compugen Ltd. | Anticorps bispécifiques anti-pvrig/anti-tigit et procédés d'utilisation |
WO2020006511A1 (fr) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Antagonistes trispécifiques |
EP3838289A4 (fr) * | 2018-07-25 | 2022-08-03 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-tigit et ses utilisations |
CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
WO2020036987A1 (fr) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides et compositions pour traitement et imagerie ciblés |
KR20210057053A (ko) * | 2018-08-23 | 2021-05-20 | 씨젠 인크. | 항-tigit 항체 |
WO2020069382A1 (fr) * | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Molécules de liaison anti-cd137 comprenant des domaines fc modifiés et leurs utilisations thérapeutiques |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
JP2022504550A (ja) | 2018-10-12 | 2022-01-13 | ゼンコア インコーポレイテッド | Pd-1標的化il-15/il-15rアルファfc融合タンパク質およびその組み合わせ療法での使用 |
AU2019375409A1 (en) * | 2018-11-05 | 2021-05-27 | Merck Sharp & Dohme Llc | Dosing regimen of anti-TIGIT antibody for treatment of cancer |
CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
KR20210113282A (ko) * | 2019-01-07 | 2021-09-15 | 아이테오스 벨지움 에스에이 | 항-tigit 항체 |
EP3914622A1 (fr) * | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Anticorps contre la sous-unité alpha d'un l'il-7r et leurs utilisations |
WO2020160560A2 (fr) * | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anticorps anti-claudine 18 et leurs méthodes d'utilisation |
CR20210462A (es) * | 2019-02-06 | 2021-12-13 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem1 y métodos relacionados |
WO2020165374A1 (fr) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Molécule bifonctionnelle comprenant il-15ra |
CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
SG11202111441QA (en) * | 2019-04-26 | 2021-11-29 | Wuxi Biologics Ireland Ltd | Bispecific antibodies against pd-1 and lag-3 |
TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
EP3977132A1 (fr) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Signature de localisation cellulaire et polythérapie |
JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
JP2022537053A (ja) * | 2019-06-21 | 2022-08-23 | シングル セル テクノロジー, インコーポレイテッド | 抗tigit抗体 |
CN114340735A (zh) | 2019-06-28 | 2022-04-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
WO2021008523A1 (fr) * | 2019-07-15 | 2021-01-21 | 上海君实生物医药科技股份有限公司 | Anticorps anti-tigit et leur application |
BR112022004831A2 (pt) * | 2019-09-19 | 2022-06-07 | Bristol Myers Squibb Co | Anticorpos que se ligam a vista em ph ácido |
JP7122354B2 (ja) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗tigit抗体および使用方法 |
US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
WO2021070181A1 (fr) * | 2019-10-08 | 2021-04-15 | Nectin Therapeutics Ltd. | Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
CN114641502B (zh) * | 2019-11-14 | 2023-11-14 | 上海药明生物技术有限公司 | 一种新的抗tigit抗体 |
WO2021113831A1 (fr) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anticorps anti-pvrig et anti-tigit pour élimination de tumeurs à base de cellules nk améliorées |
AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Ose Immunotherapeutics | Bifunctional molecules comprising an IL-7 variant |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
EP4087862A4 (fr) * | 2020-01-10 | 2024-01-10 | Shanghai Henlius Biotech, Inc. | Anticorps anti-tigit, anticorps multispécifiques les comprenant, et leurs procédés d'utilisation |
CN115052622A (zh) * | 2020-01-21 | 2022-09-13 | 信达生物制药(苏州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
US20230137966A1 (en) | 2020-02-12 | 2023-05-04 | Eli Lilly And Company | Crystallization of Antibodies or Antigen-Binding Fragments |
US20230092707A1 (en) * | 2020-03-05 | 2023-03-23 | Merck Sharp & Dohme Llc | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
KR20220154140A (ko) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pvrig 결합 단백질 및 이의 의학적 용도 |
CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
CA3176246A1 (fr) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Anticorps anti-tigit |
KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20240262915A1 (en) * | 2020-09-22 | 2024-08-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-tigit antibody and double antibody and their application |
WO2022069940A1 (fr) | 2020-09-30 | 2022-04-07 | Compugen Ltd. | Polythérapie avec des formulations d'anticorps anti-pvrig, des anticorps anti-tigit et des anticorps anti-pd-1 |
WO2022089392A1 (fr) * | 2020-10-26 | 2022-05-05 | 中山康方生物医药有限公司 | Anticorps anti-tigit, composition pharmaceutique et utilisation correspondante |
KR20230104659A (ko) | 2020-11-08 | 2023-07-10 | 씨젠 인크. | 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체 |
US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
CN114539405B (zh) * | 2020-11-23 | 2024-02-23 | 广东菲鹏制药股份有限公司 | 抗tigit抗体或其抗原结合片段 |
WO2022112198A1 (fr) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Procédé de sélection des thérapies optimales par points de contrôle immunitaire |
WO2022111612A1 (fr) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | Préparation comprenant un anticorps bispécifique anti-tigit/pd-1, son procédé de préparation et son utilisation |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
CN112538108B (zh) * | 2020-12-24 | 2022-06-28 | 郑州大学 | 高亲和pvr突变体 |
CA3196999A1 (fr) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methodes de traitement des tumeurs |
IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody preparations and methods of using them |
WO2022148781A1 (fr) | 2021-01-05 | 2022-07-14 | Institut Curie | Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire |
CN116897202A (zh) * | 2021-02-24 | 2023-10-17 | 科济生物医药(上海)有限公司 | Tigit工程化细胞及其组合物 |
WO2022212876A1 (fr) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
IL307556A (en) | 2021-04-09 | 2023-12-01 | Seagen Inc | Cancer treatment methods using antibodies against TIGIT |
EP4320155A1 (fr) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées |
WO2022214652A1 (fr) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp |
TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗tigit抗體、抗cd96抗體及其使用方法 |
EP4339208A4 (fr) * | 2021-05-10 | 2024-07-24 | Medimabbio Inc | Anticorps anti-tigit et leur utilisation |
WO2023010094A2 (fr) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Méthodes et compositions pour le traitement du cancer |
EP4403573A1 (fr) | 2021-09-15 | 2024-07-24 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Composition pharmaceutique comprenant un anticorps bispécifique anti-pvrig/tigit |
TW202328195A (zh) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合pd-1的蛋白及其醫藥用途 |
WO2023056403A1 (fr) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1 |
WO2023064958A1 (fr) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Polythérapie avec des formulations d'anticorps anti-pvrig, d'anticorps anti-tigit et d'anticorps anti-pd-1 |
CN118541389A (zh) * | 2021-11-10 | 2024-08-23 | 尖端免疫生医公司 | 抗tigit构建体及其用途 |
WO2023149978A1 (fr) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Biomarqueurs du cancer et traitements du cancer |
WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
WO2023215719A1 (fr) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anticorps anti-tigit et leurs utilisations |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
WO2023240058A2 (fr) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Méthodes pronostiques et thérapeutiques pour le cancer |
WO2024003360A1 (fr) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarqueurs et leurs utilisations pour le traitement du neuroblastome |
WO2024026496A1 (fr) | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Polythérapie avec des formulations d'anticorps anti-pvrig et des anticorps anti-pd-1 |
WO2024028386A1 (fr) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Molécule multifonctionnelle dirigée contre cd28 |
WO2024163477A1 (fr) | 2023-01-31 | 2024-08-08 | University Of Rochester | Thérapie de blocage de point de contrôle immunitaire pour le traitement d'infections par staphylococcus aureus |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1988009344A1 (fr) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Proteines mutifonctionnelles a cible predeterminee |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (fr) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Animaux transgeniques capables de produire des anticorps heterologues |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
EP0746609A4 (fr) | 1991-12-17 | 1997-12-17 | Genpharm Int | Animaux transgeniques non humains capables de produire des anticorps heterologues |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
EE05483B1 (et) | 1998-12-23 | 2011-10-17 | Pfizer, Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2359067C (fr) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Variants polypeptidiques ayant une fonction effectrice alteree |
EP2270147B2 (fr) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
NZ530583A (en) | 1999-08-23 | 2005-10-28 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
AU2003270439B2 (en) | 2002-09-11 | 2009-09-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP2364996B1 (fr) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Variantes FC optimisées et leurs procédés de génération |
CA2502904C (fr) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese |
EP1587540B1 (fr) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
UA86605C2 (ru) | 2004-01-12 | 2009-05-12 | Аплайд Молекьюлер Иволюшн, Инк. | Антитело, которое содержит вариант исходного человеческого fс-участка |
WO2005092925A2 (fr) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Variantes d'immunoglobuline a l'exterieur de la region fc |
BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
MX2007006117A (es) | 2004-11-23 | 2007-07-13 | Pip Co Ltd | Caja de llave de servicio de agua empotrada en la pared. |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
EP2343320B1 (fr) | 2005-03-25 | 2017-10-25 | GITR, Inc. | Anticorps contre gitr et leur utilisations |
RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
EP2559690B1 (fr) | 2005-05-10 | 2016-03-30 | Incyte Holdings Corporation | Modulateurs de l'indolamine 2,3-dioxygenase et leurs procedes d'utilisation |
ES2772674T3 (es) | 2005-05-12 | 2020-07-08 | Zymogenetics Inc | Composiciones y métodos para modular respuestas inmunitarias |
US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
CA3018525C (fr) | 2005-07-01 | 2023-08-01 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1) |
US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環 |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
WO2008036642A2 (fr) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase |
WO2008140603A2 (fr) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
KR101380729B1 (ko) | 2007-05-30 | 2014-04-10 | 포항공과대학교 산학협력단 | 면역글로불린 융합 단백질 |
WO2009009116A2 (fr) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Thérapies combinées utilisant des molécules de liaison au gitr |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
DE102007036200A1 (de) | 2007-08-02 | 2009-02-05 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech |
EP3492488A1 (fr) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci |
WO2009045957A1 (fr) | 2007-10-01 | 2009-04-09 | Medarex, Inc. | Anticorps humains qui se lient à la mésothéline, et utilisations de ceux-ci |
JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ido阻害剤 |
CN101939028A (zh) | 2007-11-30 | 2011-01-05 | 百时美施贵宝公司 | 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 |
AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
US8815237B2 (en) | 2007-12-05 | 2014-08-26 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
BRPI0821604B1 (pt) | 2007-12-26 | 2021-09-21 | Xencor, Inc | Polipeptídeo isolado compreendendo um fc variante de polipeptídeo de fc de igg humano, método para produzir o mesmo e uso de anticorpo |
PL2234620T3 (pl) | 2008-01-03 | 2016-09-30 | Trójterapia użyteczna przy leczeniu pacjenta zakażonego wirusem hiv | |
WO2009114335A2 (fr) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Protéines de liaison avec pd-1 |
EP2279412B1 (fr) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire |
JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン.ヴェー. | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
WO2010077643A1 (fr) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Ligands de masquage pour inhibition réversible de composés polyvalents |
NZ717213A (en) | 2008-12-09 | 2017-10-27 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010091122A1 (fr) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Polypeptides recombinants étendus et compositions les comprenant |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
CA2778115C (fr) | 2009-10-28 | 2016-04-05 | Newlink Genetics Corporation | Derives imidazole comme inhibiteurs de l'ido |
PL3279215T3 (pl) | 2009-11-24 | 2020-06-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
JP5909449B2 (ja) | 2009-12-10 | 2016-04-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 重鎖抗体を作製するマウス |
BR112012013717B1 (pt) | 2009-12-10 | 2020-01-28 | Hoffmann La Roche | anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
BR122014002928A2 (pt) | 2010-02-08 | 2015-12-29 | Regeneron Pharma | métodos de produzir um camundongo e um anticorpo e de selecionar uma região variável de cadeia pesada humana para a produção de uma proteína de ligação ao antígeno, uso de um camundongo geneticamente modificado na produção de uma proteína de ligação ao antígeno, bem como anticorpo quimérico e hibridoma |
LT2536745T (lt) | 2010-02-19 | 2016-09-26 | Xencor, Inc. | Nauji ctla4-ig imunoadhezinai |
NZ602161A (en) | 2010-03-04 | 2014-12-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
SG10201604798SA (en) | 2010-05-04 | 2016-07-28 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
CA2802017A1 (fr) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Proteines de fusion vstm3 dimeres et compositions et procedes connexes |
BR122020013427B1 (pt) | 2010-06-22 | 2021-08-03 | Regeneron Pharmaceuticals, Inc | Método para fazer um camundongo, uma célula ou tecido derivado de um camundongo e um hibridoma |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
AU2011349502B2 (en) | 2010-12-20 | 2016-12-22 | The Rockefeller University | Modulating agonistic TNFR antibodies |
WO2012115241A1 (fr) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | Anticorps fc spécifique de fcγriib |
EP3415528B1 (fr) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Protéines de fusion fc comprenant de nouveaux lieurs et arrangements |
NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 | ||
WO2012145493A1 (fr) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Anticorps et autres molécules qui se lient à b7-h1 et à pd-1 |
WO2013095738A2 (fr) | 2011-09-27 | 2013-06-27 | Mapp Biopharmaceutical, Inc. | Anticorps monoclonaux ayant des affinités altérées pour les protéines fcyri, fcyrlla et c1q humaines |
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
CA2853889A1 (fr) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Anticorps contre le csf-1r humain et leurs utilisations |
JP6322872B2 (ja) | 2011-12-19 | 2018-05-16 | ザ ロックフェラー ユニバーシティー | 非シアル化抗炎症ペプチド |
CA2861122A1 (fr) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions et procedes d'utilisation d'inhibiteurs de csf1r |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
SG11201405059XA (en) * | 2012-03-28 | 2014-09-26 | Kymab Ltd | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子1受容体(csf1r)を結合させる抗体を用いて状態を治療する方法 |
EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
MY189682A (en) | 2012-09-13 | 2022-02-25 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
JP2016500251A (ja) * | 2012-12-03 | 2016-01-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 免疫調節Fc融合タンパク質の抗癌活性の増強 |
KR20150090919A (ko) | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
PT3021869T (pt) | 2013-07-16 | 2020-09-10 | Hoffmann La Roche | Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit |
KR20230085220A (ko) | 2013-08-22 | 2023-06-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 |
EP3119913B1 (fr) * | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique |
BR112017000703A2 (pt) | 2014-07-16 | 2017-11-14 | Genentech Inc | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit |
KR102050082B1 (ko) | 2014-08-19 | 2019-11-29 | 머크 샤프 앤드 돔 코포레이션 | 항-tigit 항체 |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
IL298355A (en) | 2015-09-25 | 2023-01-01 | Genentech Inc | Anti-tigit antibodies and methods of use |
-
2015
- 2015-12-22 CN CN201580070988.1A patent/CN107207594B/zh active Active
- 2015-12-22 CA CA2971732A patent/CA2971732A1/fr active Pending
- 2015-12-22 CN CN202310623703.9A patent/CN116731176A/zh active Pending
- 2015-12-22 JP JP2016564332A patent/JP6180663B2/ja active Active
- 2015-12-22 MY MYPI2017702296A patent/MY187045A/en unknown
- 2015-12-22 MA MA40662A patent/MA40662B1/fr unknown
- 2015-12-22 MX MX2017007744A patent/MX2017007744A/es unknown
- 2015-12-22 AR ARP150104279A patent/AR103268A1/es unknown
- 2015-12-22 US US14/977,789 patent/US10189902B2/en active Active
- 2015-12-22 TN TN2017000267A patent/TN2017000267A1/en unknown
- 2015-12-22 EA EA201791171A patent/EA039219B1/ru unknown
- 2015-12-22 UY UY0001036471A patent/UY36471A/es not_active Application Discontinuation
- 2015-12-22 SG SG11201705063VA patent/SG11201705063VA/en unknown
- 2015-12-22 WO PCT/US2015/067332 patent/WO2016106302A1/fr active Application Filing
- 2015-12-22 EP EP23170440.4A patent/EP4249066A3/fr active Pending
- 2015-12-22 KR KR1020177020134A patent/KR102644115B1/ko active IP Right Grant
- 2015-12-22 EP EP15823895.6A patent/EP3237448A1/fr not_active Withdrawn
- 2015-12-22 AU AU2015369683A patent/AU2015369683C1/en active Active
- 2015-12-22 BR BR112017013385A patent/BR112017013385A2/pt active Search and Examination
- 2015-12-22 CN CN201910247168.5A patent/CN110256558B/zh active Active
- 2015-12-22 PE PE2017001141A patent/PE20171244A1/es active IP Right Grant
- 2015-12-22 TW TW104143215A patent/TWI708786B/zh active
- 2015-12-22 SG SG10202006538TA patent/SG10202006538TA/en unknown
-
2017
- 2017-06-13 MX MX2021012074A patent/MX2021012074A/es unknown
- 2017-06-19 IL IL253013A patent/IL253013B/en unknown
- 2017-06-21 PH PH12017501166A patent/PH12017501166A1/en unknown
- 2017-06-22 CL CL2017001660A patent/CL2017001660A1/es unknown
- 2017-07-12 CO CONC2017/0006989A patent/CO2017006989A2/es unknown
- 2017-07-18 JP JP2017138861A patent/JP6633032B2/ja active Active
- 2017-07-21 ZA ZA2017/04981A patent/ZA201704981B/en unknown
-
2018
- 2018-09-20 ZA ZA2018/06307A patent/ZA201806307B/en unknown
- 2018-12-20 US US16/228,095 patent/US11008390B2/en active Active
-
2019
- 2019-12-11 JP JP2019223659A patent/JP2020062026A/ja active Pending
-
2021
- 2021-02-25 AU AU2021201231A patent/AU2021201231B2/en active Active
- 2021-04-12 US US17/227,642 patent/US12060421B2/en active Active
- 2021-06-21 JP JP2021102155A patent/JP2021177759A/ja active Pending
- 2021-08-01 IL IL285287A patent/IL285287B2/en unknown
-
2023
- 2023-07-06 JP JP2023111614A patent/JP2023139046A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40662B1 (fr) | Anticorps contre tigit | |
MA43603A1 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
MX2021009852A (es) | Anticuerpos humanos para pd-1. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
MA40476A (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
MA40913A (fr) | Conjugués anticorps-médicament | |
BR112018072211A2 (pt) | anticorpos anti tl1a e utilizações dos mesmos | |
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
MX2024005841A (es) | Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias. | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
MX2023005053A (es) | Ligandos de psma para la formacion de imagenes y endorradioterapia. | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
BR112017025496A2 (pt) | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas | |
EP3492101A3 (fr) | Agents de neutralisation de la grippe | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
MA38296B2 (fr) | Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations | |
MX2018008614A (es) | Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia. | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
MA45831B1 (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation |